Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

149 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Risk classification at diagnosis predicts post-HCT outcomes in intermediate-, adverse-risk, and KMT2A-rearranged AML.
Menghrajani K, Gomez-Arteaga A, Madero-Marroquin R, Zhang MJ, Bo-Subait K, Sanchez J, Wang HL, Aljurf M, Assal A, Bacher VU, Badawy SM, Bejanyan N, Bhatt VR, Bredeson C, Byrne M, Castillo P, Cerny J, Chhabra S, Ciurea SO, DeFilipp Z, Farhadfar N, Gadalla S, Gale RP, Ganguly S, Gowda L, Grunwald MR, Hashmi S, Hildebrandt G, Kanakry CG, Kansagra A, Khimani F, Krem M, Lazarus H, Liu H, Martino R, Michelis FV, Nathan S, Nishihori T, Olsson R, Reshef R, Rizzieri D, Rowe JM, Savani BN, Seo S, Sharma A, Solh M, Ustun C, Verdonck LF, Hourigan C, Sandmaier B, Litzow M, Kebriaei P, Weisdorf D, Zhang Y, Tallman MS, Saber W. Menghrajani K, et al. Among authors: hourigan c. Blood Adv. 2022 Jan 8;6(3):828-847. doi: 10.1182/bloodadvances.2021004881. Blood Adv. 2022. PMID: 34551064 Free PMC article.
Expression of putative targets of immunotherapy in acute myeloid leukemia and healthy tissues.
Goswami M, Hensel N, Smith BD, Prince GT, Qin L, Levitsky HI, Strickland SA, Jagasia M, Savani BN, Fraser JW, Sadrzadeh H, Rajkhowa T, Ito S, Jain NA, Battiwalla M, Fathi AT, Levis MJ, Barrett AJ, Hourigan CS. Goswami M, et al. Among authors: hourigan cs. Leukemia. 2014 May;28(5):1167-70. doi: 10.1038/leu.2014.14. Epub 2014 Jan 10. Leukemia. 2014. PMID: 24472813 Free PMC article. No abstract available.
Clinical and biological predictors of outcome following relapse of CML post-allo-SCT.
Jain NA, Ito S, Tian X, Kurlander R, Battiwalla M, Lu K, Savani BN, Malkovska V, Rezvani K, Le RQ, Shenoy A, Hourigan CS, Keyvanfar K, Koklanaris E, Superata J, Muranski P, Barrett AJ, Yong ASM. Jain NA, et al. Bone Marrow Transplant. 2015 Feb;50(2):189-196. doi: 10.1038/bmt.2014.249. Epub 2014 Nov 10. Bone Marrow Transplant. 2015. PMID: 25387087 Free PMC article. Clinical Trial.
A multigene array for measurable residual disease detection in AML patients undergoing SCT.
Goswami M, McGowan KS, Lu K, Jain N, Candia J, Hensel NF, Tang J, Calvo KR, Battiwalla M, Barrett AJ, Hourigan CS. Goswami M, et al. Among authors: hourigan cs. Bone Marrow Transplant. 2015 May;50(5):642-51. doi: 10.1038/bmt.2014.326. Epub 2015 Feb 9. Bone Marrow Transplant. 2015. PMID: 25665046 Free PMC article. Clinical Trial.
Multigene Measurable Residual Disease Assessment Improves Acute Myeloid Leukemia Relapse Risk Stratification in Autologous Hematopoietic Cell Transplantation.
Mulé MP, Mannis GN, Wood BL, Radich JP, Hwang J, Ramos NR, Andreadis C, Damon L, Logan AC, Martin TG, Hourigan CS. Mulé MP, et al. Among authors: hourigan cs. Biol Blood Marrow Transplant. 2016 Nov;22(11):1974-1982. doi: 10.1016/j.bbmt.2016.08.014. Epub 2016 Aug 17. Biol Blood Marrow Transplant. 2016. PMID: 27544285 Free PMC article.
149 results